Our series encompasses a heterogeneous group of patients with different disease pathobiology with diverse genetic intricacies that may be at play (i.e., Myelodysplasia-related and post-cytotoxic therapy), possibly confounding or overriding the potential effects of RUNX1 lesions [4]. This evidence concerns the gene RUNX1 and Myelodysplasia.